Use of off-label efgartigimod (a neonatal Fc receptor blocker) for fetal acetylcholine receptor antibody–related disorder during a pregnancy stabilized maternal antibodies and led to normal fetal development and a healthy birth.
Pediatrics
|11th Mar, 2026
|The New England Journal of Medicine
Pediatrics
|11th Mar, 2026
|The New England Journal of Medicine
Pediatrics
|11th Mar, 2026
|The New England Journal of Medicine
Pediatrics
|11th Mar, 2026
|The New England Journal of Medicine
Pediatrics
|11th Mar, 2026
|The New England Journal of Medicine
Pediatrics
|11th Mar, 2026
|The New England Journal of Medicine
Pediatrics
|11th Mar, 2026
|The New England Journal of Medicine